Nurse Practitioner · Du Bois, PA
NPI
1710517560
Since 2020
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
100 Hospital Ave
Du Bois, PA, 15801
Phone (814) 375-3770
Groups this clinician bills Medicare through
Medicare paid, 2024
$56K
930 services
Medicare patients, 2024
576
Average age 74
Drug cost, 2024
$2.1M
4,256 prescriptions
Company payments, 2025
$3,263
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Todd R Sudik was code 99214 (office e&m - established), 401 times for 278 patients. In total Todd R Sudik billed 930 services in 14 codes, and Medicare paid $56K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-02-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 401 | 278 | $59.07 | $24K |
| 99214 Office E&M - Established | Facility | 320 | 227 | $58.48 | $19K |
| 99232 Hospital E&M - Subsequent | Facility | 94 | 45 | $50.50 | $4,747 |
| 99204 Office E&M - New | Office | 29 | 29 | $83.69 | $2,427 |
| 99204 Office E&M - New | Facility | 20 | 20 | $85.84 | $1,717 |
| 99213 Office E&M - Established | Office | 14 | 13 | $48.78 | $683 |
| 99309 SNF E&M | Facility | 14 | 11 | $68.79 | $963 |
| 99223 Hospital E&M - Initial | Facility | 12 | 12 | $110.75 | $1,329 |
By year: 2022 $61K for 981 services; 2023 $57K for 934 services; 2024 $56K for 930 services.
Medicare prescription drug claims, 2024
In 2024, the drug Todd R Sudik prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 662 prescriptions and refills. In total Todd R Sudik wrote 4,256 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 662 | 771 | 151 | $477K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 438 | 467 | 157 | $14K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 401 | 523 | 100 | $71K |
| Montelukast Sodium Generic | 382 | 846 | 102 | $5,043 |
| Prednisone Generic | 293 | 335 | 186 | $903 |
| Ventolin Hfa Albuterol Sulfate | 190 | 210 | 67 | $14K |
| Breo Ellipta Fluticasone/Vilanterol | 185 | 251 | 54 | $96K |
| Spiriva Respimat Tiotropium Bromide | 165 | 205 | 47 | $101K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 151 | 169 | 43 | $104K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 133 | 173 | 32 | $77K |
| Doxycycline Hyclate Generic | 104 | 105 | 82 | $576 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 82 | 102 | 29 | $18K |
| Fluticasone Propionate Generic | 80 | 145 | 31 | $1,134 |
| Incruse Ellipta Umeclidinium Bromide | 72 | 72 | 12 | $25K |
| Dupixent Pen Dupilumab | 71 | 75 | Under 11 | $283K |
Brand drugs: 2,632 claims; generic drugs: 1,624 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Todd R Sudik $3,263 ($3,263 in general payments such as food, travel and fees) from 20 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $993.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 45 | $993 |
| GlaxoSmithKline, LLC. GSK | 45 | $653 |
| Genzyme Corporation SNY | 18 | $550 |
| Regeneron Healthcare Solutions, Inc. REGN | 12 | $143 |
| Actelion Pharmaceuticals US, Inc. JNJ | 3 | $130 |
| Insmed, Inc. INSM | 4 | $105 |
| Electromed, Inc. ELMD | 5 | $96.18 |
| Verona Pharma, Inc. VRNA | 4 | $85.16 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $78.99 |
| Amgen Inc. AMGN | 4 | $78.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.